"Many metabolic diseases lack sufficient treatment options to help patients manage their disease and to treat the underlying causes to improve patient outcomes. This is an exciting opportunity for us to collaborate with AstraZeneca, a global leader in the discovery and development of prescription medicines to treat metabolic diseases, that may lead to therapeutic advances for a large number of patients globally," said Robert Habib, CEO of MiNA. Upon completion of these studies, AstraZeneca will have the option to negotiate a license agreement to further develop saRNA molecules that activate an undisclosed gene target identified by AstraZeneca. "saRNA molecules are a novel therapeutic modality that upregulate genes and have the potential to access disease-relevant targets that cannot be addressed efficiently with other approaches. We look forward to working with MiNA to investigate the potential of saRNAs further," said Shalini Andersson, Chief Scientist, New Modalities, Discovery Sciences, R&D, AstraZeneca. Harnessing an innate mechanism of gene activation, MiNA Therapeutics' platform enables the development of new medicines that restore normal function to patients’ cells.
2 other references
Latest Stories From Referenced Companies
Feb 27, 2020
Is It Right Time to Be Cautious on Caesars Entertainment Corporation (NASDAQ:CZR), AstraZeneca PLC (NYSE:AZN)? – State Reviewer
Feb 27, 2020